On September 8, 2022 The Merck Foundation (the Foundation) reported the launch of the Alliance for Equity in Cancer Care (the Alliance), a $20 million, five-year initiative, designed to make cancer care more equitable in the United States by helping patients living in underserved communities receive timely access to high-quality, culturally responsive care (Press release, Merck & Co, SEP 8, 2022, View Source [SID1234619254]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The severity of the need to take action on advancing equity in cancer care cannot be overstated and will not be overlooked," said Carmen Villar, CEO of the Merck Foundation. "We must move with urgency and work together to provide all people living with cancer access to high-quality care and treatment. The creation of the Alliance is an important step toward ensuring social determinants of health no longer factor into an individual’s ability to receive vital health care."

As part of the initiative, the Foundation is providing grants to select non-profit health care organizations to help develop and implement evidence-informed, innovative programs that advance equity in cancer care. Grantees will work collectively to improve the coordination of patient care from diagnosis through survivorship; strengthen patient engagement in treatment decisions and overall patient-provider communication; build community partnerships that address barriers to care related to social determinants of health; and provide essential psychosocial support services.

Alliance program grantees include:

Boston Medical Center (Boston, Massachusetts)
Case Comprehensive Cancer Center, Case Western Reserve University (Cleveland, Ohio)
Conquer Cancer, the ASCO (Free ASCO Whitepaper) Foundation (Montana)
Mary Bird Perkins Cancer Center (Baton Rouge, Louisiana)
Memorial Sloan Kettering Cancer Center (New York, New York)
RWJBarnabas Health (New Jersey)
University of Kentucky Markey Cancer Center (Kentucky)
Nearly 40% of Americans will be diagnosed with cancer in their lifetime. Members of racial and ethnic minority groups, those living in rural areas, low-income individuals and the uninsured are disproportionately affected by cancer, yet often have limited access to cancer screenings, care and treatment. As a result, they may experience later stage diagnoses, delays in treatment and decreased adherence to cancer therapies – with serious negative consequences to their health.

The Foundation is also supporting a National Program Office at Virginia Commonwealth University (VCU) Massey Cancer Center, in partnership with the VCU Center on Health Disparities, which will assist Alliance program grantees in building partnerships with community-based organizations and provide technical assistance to support their programs. Additionally, the National Program Office will evaluate the effectiveness of Alliance programs and identify and promote best practices to enhance the delivery of cancer care in the United States.

"There is no one-size-fits-all approach to making sure that cancer care is equitable," says Robert Winn, M.D., director of VCU Massey Cancer Center and director of the Alliance National Program Office. "We are supporting diverse approaches – driven by local community needs – to reduce the unacceptable disparities in cancer care. We hope to improve the lives of people living with cancer and help transform how health systems deliver care so that it meets the medical and social needs of patients."

The Alliance builds on the Foundation’s legacy of investing in community-focused programs that advance health equity as it follows other national, multi-year program investments to reduce health disparities and improve access to high-quality care, such as the Alliance to Advance Patient-Centered Cancer Care, Bridging the Gap in Diabetes Care and HIV Care Connect.

On September 8, 2022 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that Hervé Affagard, CEO and co-founder of MaaT Pharma, and Siân Crouzet, CFO of MaaT Pharma, will participate in three upcoming investor conferences (Press release, MaaT Pharma, SEP 8, 2022, View Source [SID1234619253]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the events are as follow:

H.C. Wainwright 24th Annual Global Investment Conference (hybrid format)

Format: virtual presentation & investor meetings
Presentation date: Hervé Affagard will present the Company and provide a corporate update. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 am EST/1:00 pm CET on Monday, September 12, 2022. A replay will be available on the investor page of Maat Pharma’s website: View Source
Link: View Source

KBC Securities Life Sciences conference (virtual)

5th edition of the "FORUM Lyon Pôle Bourse Valeurs Régionales" (on-site event)

On September 8, 2022 ISA reported that our CSO Professor Dr. Cornelis "Kees" Melief has been awarded the 2022 Pedro J. Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, ISA Pharmaceuticals, SEP 8, 2022, View Source [SID1234619252]). This Award recognizes individuals who made immeasurable contributions to the Journal for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (JITC) – the official journal of the SITC (Free SITC Whitepaper). The award will be presented at the SITC (Free SITC Whitepaper)’s 37th Annual Meeting in Boston, 8-12 November 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This award announcement follows the news that Professor Melief will be inducted as a Fellow of the Academy of Immuno-Oncology (FAIO), one of the SITC (Free SITC Whitepaper)’s most prestigious honors.

Gerben Moolhuizen, Chief Executive Officer of ISA said: "We are very proud that Kees will be receiving two of SITC (Free SITC Whitepaper)’s highest honors in recognition of his outstanding contributions to the field of cancer immunotherapy. His pioneering work holds the promise to significantly improve patient outcomes in the treatment of cancer. This is something we strive to carry forward to approved, clinically meaningful treatments. We truly value his dedication to patients and his scientific and medical guidance within our Company."

Professor Melief is a globally recognized immunology expert, specializing in cancer immunotherapy. He is known for his groundbreaking work in devising new cancer therapies. In addition to his role as CSO at ISA Pharmaceuticals, he is Emeritus Professor of Immunology at the Leiden University Medical Center in the Netherlands. He is author of more than 545 peer-reviewed publications, cited over 67.000 times, and inventor on more than 30 patents and patent applications.

For ISA, Professor Melief has been instrumental in the advancement of the versatile synthetic long peptide (SLP) immunotherapy platform. The Company’s lead product ISA101b was recently awarded Fast Track designation by the US FDA for treatment of recurrent and metastatic, human papilloma virus type 16 (HPV16)-positive oropharyngeal cancer (OPC) and also has US Orphan Drug Designation in HPV16-positive cervical cancer. ISA also has an emerging pipeline of SLP-based immunotherapies for highly prevalent diseases including PRAME-driven cancers and chronic hepatitis B.

About SITC (Free SITC Whitepaper)

Established in 1984, the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC (Free SITC Whitepaper) is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC (Free SITC Whitepaper) aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC (Free SITC Whitepaper), our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

On September 8, 2022 IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, reported that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time (Press release, ImmunoPrecise Antibodies, SEP 8, 2022, View Source [SID1234619251]). The financial results will be issued in a press release prior to the call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested in submitting questions ahead of the call are encouraged to email the Company’s investor relations contact.

Attendee URL: View Source

The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at View Source

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company’s periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

On September 8, 2022 Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, reported that Johann de Bono, Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, will present a trial in progress poster outlining the Phase 1 clinical trial design for HMBD-001 at the European Society for Medical Oncology Congress (ESMO 2022) (Press release, Hummingbird Bioscience, SEP 8, 2022, View Source [SID1234619250]). Hummingbird Bioscience management will attend ESMO (Free ESMO Whitepaper) 2022, which takes place in Paris from 9-13 September 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 clinical trial in the United Kingdom is being sponsored and managed by Cancer Research UK’s Centre for Drug Development and led by Chief Investigator, Professor Johann De Bono.

The trial began enrolling in October 2021 and is ongoing in the UK. The trial in progress poster will summarize the Phase 1 clinical trial design for HMBD-001 (NCT05057013). The Phase 1, open-label, multi-center, first-in-human trial seeks to evaluate HMBD-001 as a monotherapy and in combination with other agents to determine the maximum tolerated dose and investigate the anti-cancer activity of HMBD-001.

"We are excited to discuss our Phase 1 clinical strategy for HMBD-001 and longer-term clinical development plans with the wider oncology community at ESMO (Free ESMO Whitepaper) 2022," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer. "The unique mechanism of action of HMBD-001 gives us hope that HMBD-001 will provide significant benefit to patients with HER3-driven cancers."

Nigel Blackburn, Ph.D., Director of Cancer Research UK’s Centre for Drug Development, said: "Our Centre for Drug Development has an outstanding track record in designing and managing clinical trials, so we are really proud to see that this work, in collaboration with Hummingbird Bioscience, will be showcased to an audience of our peers at the ESMO (Free ESMO Whitepaper) 2022 conference."

ESMO Poster Presentation Details
Poster Title: A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours
Number: 493 TiP
Date: Monday, 12th September, 2022
Poster Hours: 09:00-17:00 CEST (discussion: 12:00-13:00 CEST)
Location: Poster Area, Hall 4, Paris Expo Porte de Versailles, Paris, France

About HMBD-001
HMBD-001 is a clinical-stage IgG1 antibody designed to target HER3. Discovered using Hummingbird Bioscience’s proprietary Rational Antibody Discovery (RAD) platform, HMBD-001 is now in development for the treatment of multiple solid tumors. We believe HMBD-001 is the only anti-HER3 antibody in development that has the potential to fully block both ligand-dependent and -independent HER3 activation and oncogenic signaling, by targeting a key epitope located at the interface where HER3 forms heterodimers with HER2 or EGFR. In preclinical models evaluating HMBD-001, the company has observed superior affinity and more potent tumor growth inhibition compared to existing anti-HER3 antibodies. Near-term development plans for HMBD-001 focus on a few priority, high-value indications with strong scientific rationale and supporting preclinical data, which includes HER3-driven cancers and NRG1 fusion-driven cancers.